These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 4831456)

  • 21. [The therapeutic association of L-dopa and amantadine. Preliminary results in a group of patients with Parkinson's disease].
    Gomirato G; Perfetti C
    Riv Neurobiol; 1970; 16(3):247-54. PubMed ID: 5518838
    [No Abstract]   [Full Text] [Related]  

  • 22. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor].
    Guillard A
    Brux Med; 1972 Oct; 52(10):673-80. PubMed ID: 4656191
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prolonged treatment of Parkinson's disease with amantadine and L-Dopa].
    Fieschi C; Casacchia M; Nardini M; Reitano N
    Minerva Med; 1971 Oct; 62(82):4040-2. PubMed ID: 5125075
    [No Abstract]   [Full Text] [Related]  

  • 25. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 26. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 27. [Combination of amantadine and levodopa in the treatment of Parkinson's disease. Indications. Results. Study of 58 cases].
    Sigwald J; Raymondeaud C
    Nouv Presse Med; 1972 Apr; 1(18):1237-9. PubMed ID: 5025538
    [No Abstract]   [Full Text] [Related]  

  • 28. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W; Eisenlohr JJ
    Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
    [No Abstract]   [Full Text] [Related]  

  • 29. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 31. Levodopa and amantadine in the treatment of Parkinsonism.
    Critchley E
    Practitioner; 1972 Apr; 208(246):499-504. PubMed ID: 5031037
    [No Abstract]   [Full Text] [Related]  

  • 32. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 33. L-dopa and amantadine for Parkinsonism.
    Drug Ther Bull; 1970 Aug; 8(17):65-7. PubMed ID: 5480244
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa].
    Ambrosetto C; Martinelli P
    Minerva Med; 1971 Oct; 62(82):4017-9. PubMed ID: 5125069
    [No Abstract]   [Full Text] [Related]  

  • 35. [6 months of treatment with amantadine and L-Dopa. Comparison in 2 groups of patients with parkinsonism].
    Buscaino GA; Campanella G; Zallone E
    Minerva Med; 1971 Oct; 62(82):3974-8. PubMed ID: 5125057
    [No Abstract]   [Full Text] [Related]  

  • 36. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 37. [Drug therapy of Parkinson's diseases].
    Lhermitte F; Degos CF
    Acquis Med Recent; 1972; ():73-80. PubMed ID: 4667798
    [No Abstract]   [Full Text] [Related]  

  • 38. The comparative value of amantadine and levodopa.
    Dallos V; Heathfield K; Stone P; Allen F
    Postgrad Med J; 1972 Jun; 48(560):354-8. PubMed ID: 4558895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-Dopa therapy in Parkinson's disease.
    Greer M
    J Fla Med Assoc; 1970 Jun; 57(6):23-7. PubMed ID: 4392779
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.